“Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-Oesophageal Junction Adenocarcinoma”. Molecular Medicine Communications, vol. 3, no. 02, Dec. 2023, pp. 89-92, https://doi.org/10.55627/mmc.003.02.0461.